Effects of VIP in the female genital tract.
Vasoactive Intestinal Polypeptide (VIP) has been demonstrated in the female genitourinary tract, localized in neurons which seem to innervate vessels and non-vascular smooth muscle. The present work has demonstrated that the concentration of immunoreactive VIP varies between different mammalian species and within the genital tract of the same species. Using various in vivo and in vitro preparations the peptide was found to have a dose-dependent inhibitory effect on the myoelectrical activity and contractility of the uterine muscle, and to increase myometrial blood flow. The findings support the hypothesis that VIP may play a physiological role in the local control of uterine motility and blood flow.
D000818:Animals; D002415:Cats; D005071:Evoked Potentials / Q000187:drug effects; D005260:Female; D005768:Gastrointestinal Hormones / Q000494:pharmacology*; D005836:Genitalia, Female / Q000187:drug effects*; D006041:Goats; D006801:Humans; D009215:Myometrium / Q000098:blood supply / Q000187:drug effects; D011247:Pregnancy; D011817:Rabbits; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects; D013045:Species Specificity; D013552:Swine; D014590:Uterine Contraction / Q000187:drug effects; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism / Q000494:pharmacology*
D005768:Gastrointestinal Hormones; D014660:Vasoactive Intestinal Peptide